Last edition
News about "Rhapsido"
Novartis' Rhapsido Gains UK Approval as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis has secured MHRA marketing authorisation for Rhapsido, the first oral Bruton’s tyrosine kinase inhibitor approved in the UK for adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamines.
Rhapsido | 10/08/2026 | By News Bureau
Novartis Wins Health Canada Approval for RHAPSIDO in CSU
Novartis has received Health Canada approval for RHAPSIDO (remibrutinib), a new oral treatment for adults with Chronic Spontaneous Urticari (CSU).
RHAPSIDO | 29/07/2026 | By News Bureau | 121
Novartis Secures EC Approval for First Oral Targeted CSU Drug Rhapsido
Novartis introduces Rhapsido in Europe, offering a first-of-its-kind oral targeted therapy for patients with chronic spontaneous urticaria.
Rhapsido | 28/04/2026 | By News Bureau | 184
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy